Navigation Links
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
Date:3/29/2009

ical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (ID-TLR driven by lack of blood supply).

In addition, the SPIRIT II results demonstrated that XIENCE V continues to outperform TAXUS, with XIENCE V showing continued clinical benefits at three years, including an 88 percent reduction in the risk of cardiac death and a 57 percent reduction in the risk of MACE.

"In the clinical outcomes that matter most, such as heart attack, repeat procedure at the target lesion or death, XIENCE V demonstrated a consistent reduction compared to TAXUS out to three years," said Patrick W. Serruys, M.D., Ph.D., professor of Interventional Cardiology at Thoraxcentre, Erasmus University Hospital, Rotterdam, the Netherlands, and principal investigator of the SPIRIT II clinical trial. "What's even more impressive is that the clinical differences between XIENCE V and TAXUS continue to widen between two and three years, confirming the long-term safety and efficacy of XIENCE V."

In the 300-patient SPIRIT II trial, XIENCE V demonstrated the following key results at three years:

  • An 88 percent reduction in the risk of cardiac death compared to TAXUS (0.5 percent for XIENCE V vs. 4.2 percent for TAXUS, p-value=0.024)*.
  • A 57 percent reduction in the risk of MACE compared to TAXUS (6.4 percent for XIENCE V vs. 14.9 percent for TAXUS, p-value=0.029)*.
  • An observed 52 percent reduction in the risk of heart attacks (MI) compared to TAXUS (3.3 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.20)*.
  • An observed 56 percent reduction in the risk of ID-TLR compared to TAXUS (4.2 percent for XIENCE V vs. 9.4 percent for TAXUS, p-value=0.092)*.
  • No stent thrombosis between two and three years with XIENCE V,
    '/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
5. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
6. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
9. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:8/31/2015)... ... August 31, 2015 , ... Thermi, a ... is proud to announce South Korea’s Ministry of Food and Drug Safety ... most sought-after radio frequency thermotherapy technology available in United States, South Korea, Thailand, ...
(Date:8/30/2015)... ... August 30, 2015 , ... ProTrailer Party is a new and exciting ... 30 styled and detailed presets, allowing FCPX users to immerse the audience into ... will help film makers save time while adding professional titles to every project. , ...
(Date:8/30/2015)... ... 2015 , ... Intellitec Solutions, based in Wilmington, DE, will ... & 6th in San Antonio, TX. Dedicated to bringing long term and post-acute ... over the country come to share the latest and greatest in healthcare technologies, ...
(Date:8/30/2015)... ... 30, 2015 , ... Lizzie’s Lice Pickers , a company that offers ... is currently offering lice head checks for just $10, which is a significant discount ... discount on their lice treatment products. “With kids returning to school, it is very ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and skin ... skin care experience having spent the last 25 years working in operations, purchasing ...
Breaking Medicine News(10 mins):Health News:Thermi Heats Up South Korea Announcing Global Expansion with NewRegulatory Approvals for ThermiRF™ 2Health News:FCPX Effects Developer Releases ProTrailer Party for Final Cut Pro X 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2
... 21 Meridian International,Center today announced that its ... M.D. will lead Meridian,s new Global Health,Program. The ... of Meridian,s,programs that include world affairs public briefings ... and arts and,cultural activities., "Today, 79% of ...
... SinoFresh HealthCare,Inc. (OTC Bulletin Board: SFSH), a ... today announced that the company,s CEO,Charles Fust, is ... Show., The interview gives viewers an overview ... latest press release., To ...
... It means different things to youngsters, so sex ed ... THURSDAY, Aug. 21 (HealthDay News) -- One reason why ... activity is because abstinence can mean different things to ... University of Washington study. , Teens, attitudes and intentions ...
... vaccination leading to increase, CDC report says , , THURSDAY, ... vaccinate children seems to be behind the highest rate ... Thursday. , Between Jan. 1 and July 31 of ... the United States, many of them among children whose ...
... League Baseball World Series, CHICAGO, Aug. 20 ... the winner of its annual slogan contest today,and ... coaches and parents,about tobacco addiction and the health ... tobacco. This year,s slogan contest winner is,Joe Reck, ...
... recently enacted Medicare Improvement Law immediately affects the operations ... ... nationwide, PORTLAND, Ore., Aug. 20 ... 6331, creating new legislation,protecting Medicare beneficiaries, they also established stricter,requirements for ...
Cached Medicine News:Health News:Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Center's Global Health Program 2Health News:[video] Charles Fust, CEO of SinoFresh HealthCare, Inc. Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show 2Health News:Abstinence-Only Programs Fall Short of Teens' Needs 2Health News:Measles Cases Highest Since 1996 2Health News:Measles Cases Highest Since 1996 3Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:Medicare Advantage Plans Struggle to Comply With New Federal Law 2
Double-ended. 3 mm x 5 mm curette end and 3 mm spatula end....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
2 mm tip....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: